What is Zacks Research’s Estimate for IOVA Q2 Earnings?

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) – Investment analysts at Zacks Research boosted their Q2 2026 earnings estimates for shares of Iovance Biotherapeutics in a report released on Thursday, July 23rd. Zacks Research analyst Team now expects that the biotechnology company will post earnings of ($0.17) per share for the quarter, up from their previous forecast of ($0.18). The consensus estimate for Iovance Biotherapeutics’ current full-year earnings is ($0.60) per share. Zacks Research also issued estimates for Iovance Biotherapeutics’ Q3 2026 earnings at ($0.14) EPS, Q4 2026 earnings at ($0.12) EPS, FY2026 earnings at ($0.62) EPS, Q1 2027 earnings at ($0.10) EPS, Q3 2027 earnings at ($0.08) EPS, Q4 2027 earnings at ($0.07) EPS, FY2027 earnings at ($0.36) EPS, Q1 2028 earnings at ($0.05) EPS and FY2028 earnings at ($0.10) EPS.

Iovance Biotherapeutics (NASDAQ:IOVA) last posted its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.19). Iovance Biotherapeutics had a negative net margin of 123.92% and a negative return on equity of 50.17%. The firm had revenue of $71.43 million during the quarter, compared to the consensus estimate of $77.84 million. During the same quarter in the previous year, the firm posted ($0.36) EPS. The business’s revenue for the quarter was up 44.9% compared to the same quarter last year.

Other analysts also recently issued reports about the company. Chardan Capital cut their target price on Iovance Biotherapeutics from $16.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Iovance Biotherapeutics in a research report on Thursday, July 2nd. Five analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Iovance Biotherapeutics currently has a consensus rating of “Hold” and an average price target of $8.43.

Iovance Biotherapeutics Price Performance

Iovance Biotherapeutics stock opened at $4.90 on Monday. The stock’s fifty day moving average price is $4.24 and its two-hundred day moving average price is $3.66. Iovance Biotherapeutics has a one year low of $1.76 and a one year high of $5.64. The firm has a market cap of $2.19 billion, a PE ratio of -5.16 and a beta of 0.70.

Institutional Investors Weigh In On Iovance Biotherapeutics

A number of large investors have recently modified their holdings of IOVA. Aberdeen Group plc lifted its position in shares of Iovance Biotherapeutics by 25.1% during the 4th quarter. Aberdeen Group plc now owns 759,522 shares of the biotechnology company’s stock worth $2,073,000 after buying an additional 152,312 shares during the last quarter. Knott David M Jr bought a new position in Iovance Biotherapeutics in the first quarter valued at about $5,616,000. Profund Advisors LLC grew its position in Iovance Biotherapeutics by 149.7% in the fourth quarter. Profund Advisors LLC now owns 260,660 shares of the biotechnology company’s stock valued at $712,000 after acquiring an additional 156,253 shares during the last quarter. Vanguard Group Inc. grew its position in Iovance Biotherapeutics by 13.1% in the fourth quarter. Vanguard Group Inc. now owns 27,207,079 shares of the biotechnology company’s stock valued at $74,275,000 after acquiring an additional 3,148,096 shares during the last quarter. Finally, Leonteq Securities AG acquired a new position in Iovance Biotherapeutics during the fourth quarter worth about $532,000. Institutional investors and hedge funds own 77.03% of the company’s stock.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.